跳至主要内容
临床试验/EUCTR2019-004255-36-SE
EUCTR2019-004255-36-SE进行中(未招募)1 期

Cesar - an open, randomized controlled phase II study, comparing Naltrexon and Fluoxetin treating Compulsive Sexual Behavior Disorder.

Karolinska Universitetssjukhuset0 个研究点目标入组 80 人开始时间: 2020年6月1日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Age 18 - 65 years
  • - Signed Informed Consent
  • - Able to understand Swedish language, written and spoken. Be able to use internet.
  • - Willingness to attend all visits including blood sampling and urine analysis
  • - Fulfill the criterias of Compulsive Sexual Behaviour Disorder
  • - Women of childbearing potential must practice a highly effective method of birth control throughout the study
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 80
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - AST and ALT greater than 3 x ULN
  • - Ongoing treatment with opioids or benzodiazepines
  • - Self reported use of illegal drugs during the last month, or presence of abuse in urine at inclusion
  • - Hazardous consumption of alcohol during the last month, or alcohol abuse. AUDIT >8.
  • - Severe psychiatric desease e.g. psychosis or major depression with immediate need of helath care
  • - History of hepatic- or renal impairment.
  • - Severe somatic condition including unstable heart disease or uncontrolled seizures.
  • - Current treatment with SSRI or Naltrexone, or history of allergy to these treatments
  • - Changes in treatment regimen or doses the last three month of following therapies: anti depressive, ADHD (minor changes weekdays but not weekends may be accepted, as judged by the investigator) antimanic agents, anti psychotic, cortisone, testosterone, L-Dopa
  • - Current use of medications which have serious interactions with fluoxetine e.g. MAO-inhibitors, cocillana-etylmorfin and metoprolol.
  • - Pregnancy, lactating or inadequate birth control within women of childbearing potential.
  • - Current psychotherapy. Family counselling may be accepted, as judged by the study psychologist.
  • - Any psychological condition that may interfere the patients health or the scientific parts of the study, e.g. intelectual disability
  • - Already enrolled into a clinical trial

研究者

相似试验

进行中(未招募)
不适用
Safety and immunogenicity study of GSK Biologicals’ candidate tuberculosis vaccine (692342) when administered to healthy infants.Healthy volunteers (evaluation of safety and reactogenicity of TB vaccine when administered in healthy infants)
EUCTR2012-004380-44-Outside-EU/EEAGlaxoSmithKline Biologicals301
已完成
2 期
An open label study to investigate the safety and efficacy of treatment with ACH-0143102 and sofosbuvir in hepatitis C patientsInfection - Other infectious diseasesHepatitis C
ACTRN12614000307606Achillion Pharmaceuticals, Inc36
已完成
2 期
Phase II, randomized, controlled, open-label study ofPegylated IFN alfa-2b with SARS-CoV-2
CTRI/2020/06/026087Cadila Healthcare Limited Zydus Research Center40
进行中(未招募)
1 期
Clinical trial with MBK-01, intestinal microbiota capsules, for the treatment of patients with recurring diverticulitis
CTIS2023-506224-87-00Mikrobiomik Healthcare Company S.L.81
进行中(未招募)
1 期
A randomized, multicentre, open-label, Phase II study of the efficacy and safety of lapatinib plus epirubicin and cyclophosphamide (EC90-L) followed by weekly paclitaxel and lapatinib (PX-L) compared with EC90 followed by weekly paclitaxel and trastuzumab (PX-T), as neoadjuvant therapy in patients with previously untreated ErbB2-overexpressing Stage I - IIIA invasive breast cancer with primary tumour size > 1cm. - ELATEpatients with previously untreated ErbB2-overexpressing Stage I - IIIA invasive breast cancer with primary tumour size > 1cm.MedDRA version: 12.1Level: LLTClassification code 10006187Term: Breast cancer
EUCTR2010-018389-22-HUGlaxoSmithKline Research & Development Ltd